论文部分内容阅读
目的探讨联合使用前列地尔和贝那普利用于糖尿病肾病蛋白尿治疗的临床效果。方法 66例糖尿病肾病蛋白尿患者,按照治疗方式的不同分为对照组和观察组,每组33例。对照组患者使用贝那普利进行治疗,观察组患者在对照组治疗的基础上加用前列地尔进行治疗,观察两组患者治疗前后24 h尿蛋白含量和24 h尿微白蛋白排泄量情况,比较两组患者不良反应发生率。结果治疗后,观察组患者24 h尿蛋白含量和24 h尿微白蛋白排泄量情况明显优于对照组,观察组患者不良反应发生率明显低于对照组,差异均具有统计学意义(P<0.05)。结论在糖尿病肾病蛋白尿临床治疗的过程中采用前列地尔和贝那普利联合治疗的方式具有极高的临床应用价值,值得推广应用。
Objective To investigate the clinical effect of combined use of alprostadil and benazepril in the treatment of diabetic nephropathy. Methods 66 diabetic nephropathy patients with proteinuria were divided into control group and observation group according to different treatment methods, with 33 cases in each group. The patients in the control group were treated with benazepril. The patients in the observation group were treated with alprostadil on the basis of the control group. Urine protein and 24-hour urinary albumin excretion at 24 hours before and after treatment were observed in both groups , The incidence of adverse reactions in two groups were compared. Results After treatment, 24 h urinary protein and 24 h urinary albumin excretion were significantly better in the observation group than in the control group. The incidence of adverse reactions in the observation group was significantly lower than that in the control group (P < 0.05). Conclusion The combination of alprostadil and benazepril in the clinical treatment of diabetic nephropathy proteinuria has a high clinical value and is worth popularizing.